4.3 Review

Homoarginine in the cardiovascular system: Pathophysiology and recent developments

期刊

FUNDAMENTAL & CLINICAL PHARMACOLOGY
卷 37, 期 3, 页码 519-529

出版社

WILEY
DOI: 10.1111/fcp.12858

关键词

amino acids; cardiovascular; homoarginine; mortality; nitric oxide

向作者/读者索取更多资源

Recent research has identified the endogenous non-proteinogenic amino acid L-homoarginine (L-hArg) as a novel biomarker and a direct contributor to cardiac dysfunction in cardiovascular disease. The association between low L-hArg levels and adverse cardiovascular events and mortality suggests that nutritional supplementation may be effective in improving cardiovascular health.
Upcoming experimental and epidemiological data have identified the endogenous non-proteinogenic amino acid L-homoarginine (L-hArg) not only as a novel biomarker for cardiovascular disease but also as being directly involved in the pathogenesis of cardiac dysfunction. The association of low L-hArg levels with adverse cardiovascular events and mortality has proposed the idea of nutritional supplementation to rescue pathways inversely associated with cardiovascular health. Subsequent clinical and experimental studies contributed significantly to our knowledge of potential effects on the cardiorenal axis, acting either as a biomarker or a cardiovascular active agent. In this review article, we provide a comprehensive summary of the L-hArg metabolism, pathophysiological aspects, and current developments in the field of experimental and clinical evidence in favor of protective cardiovascular effects. Establishing a reliable biomarker to identify patients at high risk to die of cardiovascular disease represents one of the main goals for tackling this disease and providing individual therapeutic guidance.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.3
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据